With five world-class medical centers, the University of California is well positioned to create and introduce new health care inventions into the marketplace. From vaccines to new high-tech diagnostics, health care advances comprise the largest sector of the Technology Transfer Program' s portfolio, making up 70 percent of new inventions. Among UC' s many inventions are two health care technologies that were patented seven to 10 years ago. These inventions, just entering the marketplace, include the first and only material that promotes new bone growth and a glucose-monitoring device that could help diabetics better manage the treatment of their disease.
The first material that mimics components of bones and promotes new bone growth (Pepgen P-15) was licensed in 1992 and already is being marketed for dental use by Dentsply CeraMed Dental of Lakewood, Colorado (www.ceramed.com). The technology is based on P-15, a 15-amino acid peptide sequence discovered at UC San Francisco.
Andrew Tofe, who took the product through clinical testing for dental applications, extended the license and started a new company, CeraPedics, that will use the material for orthopedics, starting with spinal surgery. Although the company must develop formulations, conduct clinical testing and get Food and Drug Administration (FDA) approval, Tofe estimates that the product could be in clinical testing within three years.
"There is a huge need and large market for this product," Tofe predicts. "If it performed well in the mouth, which is not a very clean environment, I expect it to work as well in the much more sterile environment within the body. It could be a godsend for patients suffering from degenerative disc disease of the spine."
Two other companies also have licensed the P-15 peptide:
InCube has the right to use the peptide for coating a wide range of human medical devices, including cardiovascular catheters, implantable drug pumps, cochlear, penile, and breast implants, pain management systems, and noncardiac pacemakers.
CardioVasc can use the peptide for cardiovascular devices, cardiac pacemakers, vascular grafts, and heart valves. The peptide is believed to promote endothelial healing over the surfaces after implantation of these devices. CardioVasc has initiated a 30-patient European clinical trial focused on the use of its first device, a small diameter stent graft treated with the P-15 peptide, in the treatment of lesions in vein bypass grafts.
An article in the New York Times heralded Food and Drug Administration approval of a wristwatch like device (the GlucoWatch ® Biographer, www.glucowatch.com) that could help millions of people who suffer with diabetes better manage their disease and improve the quality of their lives. Cygnus, of Redwood City, California, licensed the innovative UC technology in 1995. It began to market the GlucoWatch ® Biographer in Europe in 2001 and believes it will have it in commercial use in the U.S. in 2002.
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Using technology pioneered at UC San Francisco, the pain-free, automatic device measures sugar levels every 20 minutes for up to 12 hours by sending tiny electric currents through the skin. An alarm sounds if sugar levels are too high or too low or if the readings rapidly decline. The device initially is intended to supplement the finger stick and provide diabetics with more information than ever before. It can help them make better-informed decisions about diet, medication, and physical activities and, thus, have the best possible control over their disease.
The device is now available by prescription for diabetics who are at least 18 years old, and the application to make it available to diabetics seven to 17 years old has been granted an expedited review status by the FDA.
Stroke patients considered inoperable or at very high risk for surgery because of a brain aneurysm are now benefiting from the Guglielmi Detachable Coil, developed at UC Los Angeles and licensed to Boston Scientific/Target. The product, the first to receive FDA approval for treatment of high-risk stroke patients, was developed in 1989 by Guido Guglielmi, M.D., as an alternative to surgery.
Clinical trials nationwide verified that patients have more favorable outcomes with the procedure, with close to 60 percent showing a complete recovery.
A soft platinum alloy delivered to the site by a micro-catheter, the coil in effect plugs the aneurysm so that it is completely isolated from blood circulation and unable to rupture.
More than 150 centers in the U.S. and 1,000 centers worldwide now perform the procedure and over 85,000 patients have received the treatment. The number of coils used exceeds 400,000.
The next generation of coil, also pioneered at UCLA, accelerates the formation of connective tissue at the neck of the aneurysm, possibly allowing for a true healing of the defect.
The Guglielmi Coil earned more than $6 million in royalty income in FY01, and Treatment for Intercranial Aneurysms thereby ranks as the second top-earning commercialized invention in the UC portfolio this year.
Another top-earning technology, from UC Irvine, is Dynamic Cooling Device. The device, now used worldwide, selectively cools the superficial layers of human skin during laser surgery allowing higher light dosages, more effective treatment with less pain, and less post-operative scarring. The hope is that it will improve the effects of cosmetic laser surgery as well as surgery to remove birthmarks. Dynamic Cooling Device is one of the top five revenue-producing inventions in FY01, accumulating $3.6 million of royalty income for the University.
It is no coincidence that California is the numberone agricultural producer and exporter in the United States and the home of the University of California. You only have to go as far as your supermarket or local farmers' market to experience the impact that technology transfer at the University of California has made on agriculture.
Varieties of strawberries, almonds, walnuts, grapes, cherries, artichokes, peaches, avocados, asparagus, mandarin oranges, prunes, beans, alfalfa, wheat, and other crops, many developed at UC Davis and UC Riverside, are all licensed from the University to growers in the State and throughout the world.
Because UC varieties come out of research programs, they have value-added traits such as disease resistance, high productivity, long growing seasons, or growth cycles tailored to varied climates. Most varieties are developed to advance the State' s agricultural base, but what does well in California' s diverse climates also thrives in similar environments found worldwide.
No matter how you slice it, the strawberry historically is the most significant agricultural product developed and licensed by the University.
California leads the nation in the production of strawberries, accounting for 83 percent of the country' s total fresh and frozen strawberry production. If all the strawberries produced in California were laid berry to berry, they'd wrap around the world 15 times. That' s enough strawberries to provide every U.S. household with 12 pint baskets, reports the California Strawberry Commission.
UC has bred a total of 32 strawberry varieties, including the Camarosa, the Diamante, and the Aromas. The Camarosa has the distinction of having the largest market share of any strawberry variety sold in the world. It alone generated $2.7 million of royalty income in FY01 and is among the University' s top five incomeproducing commercialized products. Newly released UC varieties, Ventana and Camino Real, are expected to surpass Carmarosa' s popularity. California' s 1,100 vineyards produce 92 percent of all grapes in the nation. The University has licensed nine grape varieties and four rootstocks. The Redglobe Grape, developed by UC Davis in 1979, brought in $1.6 million in fees and royalties throughout its patent life.
Walnuts are another of the State' s favorite crops, with California grown walnuts accounting for 99 percent of the nearly $300 million in the U.S. and overseas markets. The Chandler Walnut, developed at UC Davis in 1977 (and now off patent), is the numberone shelling variety sold in the U.S. and accounts for almost 30 percent of some 303,000 tons of walnuts grown in California in 2001, reports the Walnut Marketing Board of California.
A new red "designer" walnut named the Robert Livermore Walnut was bred in 1999 at UC Davis and is already in the marketplace. Although the meat and shell are normal, the walnut has a red skin and is aimed at the gourmet chef who wants to serve food with an extra flair. The impact of biotechnology-related agricultural inventions will soon make its presence known, and provide a strong base for future licensing activity without compromising the importance of UC plant varieties. Beginning in the 1980s, some $105 million in fees and royalties came into UC from these futureoriented inventions.
Cultivating
One promising venture that is expected to lead to genetically advanced fruit and seed crops has its roots in a research relationship between Malibu-based Ceres, Inc. and four UC campuses -UC Berkeley, UC Davis, UC Los Angeles and UC Santa Cruz.
Using state-of-the-art genomic technologies, Ceres' emphasis is on developing breakthrough plants and products with better yield, size, quality, and vigor. Started in 1997, the company has 105 employees, including 30 with Ph.Ds.
A license recently has been negotiated with Ceres that provides the company with rights to technologies that could benefit growers through improved crop yields and consumers through improved product quality.
UC's impact on agriculture has taken many forms. UC breeding programs have developed new varieties of fruits and vegetables, fruits that are sweeter and stay fresher longer, and plants that resist disease. And just as UC has helped shape the foundation of agriculture in California, it plans to play a significant role in the future of modern agriculture.
Almost every aspect of our future will be touched by high-technology innovations. From information technology to robotics, the following stories highlight that many of these inventions will have a UC campus as their place of origin.
One of the most recent high-technology success stories comes out of UC Santa Barbara where a 1990 UC patent led to the launch in 1998 of Agility Communications (www.agility.com). The company' s breakthrough in widely tunable lasers allows one laser to do what it now takes more than 100 separate devices to do.
The privately-held company has been highlighted in several "hot companies to watch" lists, in publications including BusinessWeek, Lightwave and Upside magazines and recently received a Comet Award from Communications System Design magazine. This award honors small to medium-sized companies in communications that have demonstrated vision, innovation and risk-taking. During the award presentation to Agility, the magazine noted that the tunable laser market is one of the hottest and fastest-growing areas in communications and Agility, with its innovative technology, is well positioned within this market.
Agility is one of two high-tech firms started by Larry A. Coldren, a professor at UC Santa Barbara, and some of his graduate students. Based on more than a half-dozen patents with UC Santa Barbara, the company has pioneered ways to reduce the costs and complexity of supporting agile networks.
When the technology first came out of the research laboratory in 1988, its potential wasn't apparent.
However, the rapid evolution of fiber optic communication created a market demand for being able to send more than one channel down a fiber and the value of the technology came to light.
Agility' s first products are expected to help communications providers to increase network capacity, lower costs, maximize existing network resources, streamline the planning process for network growth, and dynamically provide bandwidth.
Coldren is chairman of the board of directors of the company, but has returned to UC Santa Barbara where he continues to do what he likes best -research and mentoring dozens of students in the latest developments in optoelectronic materials and devices.
He maintains that one of the biggest advantages to come out of this partnership has been bringing former UCSB graduate students, who had gone on to work at high-tech companies around the world, back to the Santa Barbara area to help advance its economy by working for Agility and other cutting-edge firms.
Another fertile region for advancing high-technology is San Diego, home to 216 biotech companies, 161 medical device companies and UC San Diego. A very real and humanitarian drive is behind a sixmonth-old company, Robomedica, Inc., a Santa Monica-based UC licensee that expects to play a pivotal role in the rehabilitation of patients who have suffered paralysis from spinal cord or traumatic brain injuries or strokes.
Alan Olsen had no idea that he would end up president of a robotics company three years ago when his son became paralyzed in a diving accident.
Olsen had been retired for more than nine years from a spinal implant company he had founded when he came across a news story describing research at UC Los Angeles that had the potential to help patients with paralysis.
"I read the article on a Monday describing the work being done at UCLA and on Wednesday was flying to California from my home in Florida to find out more," said Olsen.
He met V. Reggie Edgerton, a professor of physiological sciences and neurobiology at UCLA and a leading researcher in recovery of stepping following spinal cord injury.
"We were like two individuals floating in space who had been searching for each other. He had the technology and I had the business background," said Olsen, who has since relocated to the Los Angeles area.
The UC researcher believed that some and possibly many patients with incomplete spinal cord injuries could, with repetitive motion and exercise, be retrained so that they would learn to step and walk with assistance. "It may sound like a small advance, but just helping paralyzed persons move their legs in a standing position can reduce common side effects like osteoporosis and thrombosis," said Olsen.
The team from UCLA had been working with the robotics laboratories at UC Irvine and the Jet Propulsion Laboratory at the California Institute of Technology to develop the technology that was eventually licensed by the company. "Physical therapy may help patients with paralysis, but it is much too expensive for all but a few to afford," said Edgerton.
"Our hope is that the robotics technologies for which we have patents pending will simulate the work of several physical therapists and actually improve the effectiveness of their training."
The company's first goal is to market manual systems similar to those in current clinical trials that are under way now to make certain that the concept works and should be part of treatment guidelines for patients with paralysis, said Olsen. Robotic devices will follow.
Olsen sees the time when the company' s products will complement evolving surgical or pharmacological treatments to effectively "cure" paralysis.
"Because of how valuable this advance will be for patients with paralysis, the support has been tremendous," Olsen said.
The University increasingly is working with start-up companies that are built on a UC invention and offer promise of fueling the State's economy in the 21 st century.
At last count, UC had identified more than 160 startup firms whose founding was based on a technology transfer agreement with UC. Thirty-five percent of the companies are in fields of biotechnology and genomics and 30 percent in pharmaceuticals and drug development. Other start-up companies are built on UC inventions in medical devices, advanced materials, and software and electronics.
Research on UC' s start-up companies shows that they generally involve high-risk technologies with long research and development periods and often are founded by a UC inventor.
Most of the companies are based in California, situated to help the State' s future economy and labor force. Some 61 companies are located in the San Francisco Bay Area, 36 in the San Diego region, 27 in the Los Angeles and Irvine areas and nine in Santa Barbara. The remainder are in less populated areas of California and in other states.
Profile of a start-up company
Even in poor economic times, start-up companies can thrive if they are based on the right technology. What started as a research advance in an electronics laboratory at UC Berkeley is now turning into revolutionary products for UC licensee Alien Technology Corp. of Morgan Hill, California (www.alientechnology.com).
Alien produces displays for wallet-sized smart cards that have applications in areas of banking, information technology, government, health care and transportation.
Widely used in Europe and Asia, the cards contain an embedded electronic microchip that stores electronic data and programs and can function as a small identification card. Alien already produces the displays for Gemplus, a French firm that makes two million cards per day, 40 percent of the world' s total.
Most recently, Alien has positioned itself as the world' s leading source for low-cost radio frequency identification tags that can store information about such items as food, clothes, drugs, and auto parts and can be used in toll collection, phone cards and a myriad of other products.
Alien's product costs five cents instead of the 50-cent to several-dollar price tag of existing tags, according to Jeffrey Jacobsen, company president and chief executive officer (CEO).
Fueling start-ups with ideas and inventions
He expects the economic savings to achieve deep market penetration in new arenas, including inventory tracking, product availability, theft and security protection, and advanced consumer products, such as smart washing machines, refrigerators, and ovens.
In January 2002, Alien announced that it had formed a partnership with a company in Finland (UPF Kymene) to begin manufacturing the low-cost radio frequency tags or smart labels later in the year.
Alien's technology is built on a process called Fluidic Self-Assembly (FSA™), which permits the efficient assembly of integrated circuits (NanoBlock™ ICs) into a variety of substrates, from glass to flexible plastic, in a single-process step. The technology was developed by J. Stephen Smith, a professor of electrical engineering at UC Berkeley, and Hsi-Jen Yeh, a UC Berkeley doctoral student. Smith formed a small company in 1994 to advance the technology. In 1998, Jacobsen was brought in as president and CEO.
According to a growing number of articles on this small company, Jacobsen has been able to align with major industries worldwide, garner more than $90 million in venture capital, open an 85,000 square-foot headquarters and production facility in Morgan Hill, and begin to move the technologies into the marketplace. The real test of success has yet to come from revenue streams, but Jacobsen is convinced that Alien has been at the right place at the right time -with the right technology. While other companies have been struggling, he said that venture capital has been pumped into Alien and the company' s non-public stock shares have continued to increase in value.
If the products based on technology Alien licensed from UC turn out to be as successful as its charismatic leader predicts, the technology transfer process will have created a win-win enterprise for the inventors, the University and the State' s economy for decades to come.
Technology Transfer Activity INVENTION REPORTING
During the twelve-month period ending June 30, 2001, a total of 957 inventions were disclosed by faculty and researchers at the nine UC campuses. This represents an 11% increase when compared with the 865 new inventions reported in FY00 (Exhibit 1).
EXHIBIT 1
INVENTIONS REPORTED
Inventions in life science disciplines including medicine and biotechnology accounted for over 70% of the new inventions, while those from the physical sciences and engineering accounted for most of the balance. Over time, the pattern of invention disclosure by broad technology area has approximated the distribution of extramurally-sponsored research at the University. The distribution of newly reported inventions by campus is shown in Exhibit 2. Systemwide patent activity for FY01 is presented in Exhibit 4. Exhibit 5 shows trends in patent filings over the past five years. Acquiring adequate patent coverage for all aspects of a new technology may require more than one patent filing for a given invention. Such secondary filings frequently lead to the issuance of multiple patents related to a single initial invention. The growth in the number of inventions reported throughout the UC system has resulted in an increase in patent filings which has given rise to the high level of patents issued to UC over the past several years (Exhibit 6).
EXHIBIT 5
TRENDS IN UC PATENT FILINGS PATENT ACTIVITY
A patent is a form of intellectual property protection granted by the U.S. or a foreign government that affords the patent holder the right to exclude others from making, using, or selling the patented invention for a defined period of time, generally for twenty years from the date the patent application is first filed. Both U.S. and foreign patent rights often must be pursued for an invention in order to maximize the likelihood of successful commercialization. 
EXHIBIT 4
PATENT ACTIVITY
U.S. PATENTS ISSUED TO UC
At the end of FY01, there were 2,267 US and 1,780 foreign patents in the systemwide portfolio (Exhibit 7). The number of U.S. patents in each campus portfolio is presented in Exhibit 8. At the close of the fiscal year, the systemwide portfolio totaled 1,242 licenses. In managing these agreements, the University must collect monies when due and monitor progress to ensure that the licensees exercise due diligence in developing inventions toward commercial application.
LICENSING AND RELATED ACTIVITY
A license agreement grants a licensee access to a University invention in exchange for the licensee' s commitment to provide the resources required to further develop and commercialize the invention. Utility licenses generally cover useful processes, machines, manufactured items, or compositions of matter protected by utility patents. Most utility patents are licensed exclusively to a single company for a defined use, although non-exclusive licensing of utility patents sometimes occurs. In contrast, plant licenses cover sexually and asexually reproduced plant varieties and are licensed non-exclusively to multiple growers and distributors worldwide.
The provisions of the license define the rights and responsibilities of the two parties. In the typical license agreement, the licensee is granted access to an early stage invention that is protected by a University patent. In exchange, the licensee makes a commitment to commercialize the invention and pay the University agreed-upon fees, reimbursement of expenses and royalty payments when products reach the marketplace. The specific terms of the agreement are determined through a complex negotiation process. Prior to the execution of a license, certain shorter-term agreements are sometimes executed. A secrecy agreement is used in conjunction with marketing and affords a potential licensee access to confidential information that assists the company in determining if it has an interest in pursuing a license for a given technology. Well over 1,000 secrecy agreements are entered into by the University system each year. A letter agreement generally is used to confirm a company' s intent to negotiate a license and often commits a company to pay certain fees or patent costs while negotiations are underway. Option agreements are similar in scope to license agreements and protect a licensee' s interest in an invention while more in-depth technical or marketing research is performed.
In FY01, UC entered into 387 licenses and related technology transfer agreements. As indicated in Exhibit 9, these included 142 utility license agreements, 68 plant license agreements, 52 option agreements, and 125 letter agreements.
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Exhibits 10 and 11 show the five year trend in the size of the portfolio of UC utility and plant licenses. Each year some agreements expire or are terminated. In general, the total number of active utility agreements has continued to rise due to increased licensing activity throughout the system. In the plant area, the expiration of patents for peach, grape, and asparagus varieties contributed to the decrease in the overall portfolio of plant licenses in FY01. Strawberry licensing continues as a strong component of the plant program and modifications in UC plant licensing practices overseas are being made in order to promote the more controlled distribution of a range of UC cultivars.
Exhibit 12 shows the number of utility license agreements associated with each campus. In addition, the Berkeley campus has 4 plant licenses in its portfolio, Davis has 350, and Riverside has 99. 
EXHIBIT 12
TOTAL UTILITY LICENSES BY CAMPUS*
ROYALTY AND FEE INCOME
The portion of total licensing revenue from royalty and fees in FY01 was $72.9 million. This income derived from 868 inventions. When the $200 million Human Growth Hormone Settlement is excluded from FY00 royalties (see Exhibit 13), the FY01 amount represents a 7.6% increase over the prior year.
FY01 royalty and fee income includes $71,076 UC realized from the sale of equity previously acquired under three licensing agreements. As a result of these transactions and the execution of 12 licenses in FY01 that included equity as a partial consideration, at the end of the fiscal year the University held equity related to technology transfer activities in 38 companies. Stock in eight of these companies was traded in public markets and was valued at $3.7 million.
Income from the top five commercialized UC inventions (i.e. inventions that have reached the marketplace and are generating earned royalties) contributed $39.1 million in FY01, accounting for 54% of total royalty and fee income (Exhibit 15). The top twenty-five royaltyearning technologies collectively accounted for $55.8 million or 77% of this total. Three utility inventions, Dynamic Skin Cooling Device, Urethane Vehicles/Topical Use, and Fluorescent Dyes-Calcium, appeared on the list of top-earning inventions for the first time in FY01. UC is
Technology Transfer Revenues TOTAL LICENSING REVENUES
Total licensing revenue, the income the University receives from its agreements with industry, was $82.9 million in FY01 (Exhibit 13). There are several components of total licensing revenue: Agreement issue fees, maintenance fees and other "milestone" payments are received on specific dates or at specific points in the product development process. These payments encourage companies to diligently pursue product commercialization. Reimbursements represent the recovery of patent expenses. Finally, earned royalties are received on products derived from University inventions that are being sold in the marketplace.
EXHIBIT 13
TOTAL LICENSING AND REVENUE* (Millions)
* In FY00, the University received a $200 million payment as settlement for a long-standing infringement suit involving the University's Human Growth Hormone patent. Because of the unique nature and magnitude of this settlement, monies attributable to the settlement are excluded from the year-by-year trend analyses in this and similar figures in the remainder of this report. 
INCOME FROM PATENT/ LEGAL EXPENSE REIMBURSEMENTS
Expense reimbursements from licensees primarily cover costs incurred to secure, maintain, and protect patent rights associated with an invention. Because of the highly technical nature of UC inventions, the University uses specialized attorneys to draft and prosecute its inventions in the U.S. and abroad. Costs associated with this aspect of the technology transfer program are substantial. Obtaining a licensee' s commitment to reimburse legal costs for an invention is a high priority objective of license negotiations, and reimbursements, therefore, are considered to be part of total licensing revenue. In FY01, the University received $10.0 million in expense reimbursements from its licensees (Exhibit 16).
EXHIBIT 16
INCOME FROM REIMBURSEMENT OF PATENT EXPENSE* (Millions)
*For financial reporting purposes, expense reimbursements are treated as an offset to legal and other direct expenses (see section on Legal and Other Direct Expenses). 
Technology Transfer Expenses LEGAL AND OTHER DIRECT EXPENSES
Legal and other direct expenses totaled $22.3 million in FY01 (Exhibit 17). Approximately 80% of this amount, $18.0 million, was associated with patent prosecution, which includes payments to outside counsel for drafting patent applications and other routine costs associated with securing and maintaining patent protection for University inventions. The remaining $4.3 million was for non-routine disputes and legal actions. 
Gross Legal Expenses Net Legal Expenses
The negotiated terms of certain license agreements entitle the University to receive reimbursement of specific legal expenses. In FY01, these reimbursements totaled $10.0 million (see p. 21), resulting in net legal expenses of $12.3 million (Exhibit 17). Exhibit 18 provides a breakdown of FY01 net legal expenses (i.e., legal expenses after reimbursements) by category. Patent prosecution costs, which are spread among a large number of inventions, accounted for close to 60% of these expenditures. Most of the $4.1 million for legal defense was related to a patent title dispute involving a single case. The remainder of net legal expenses were incurred in connection with a number of smaller legal actions and disputes. Year Ended June 30, 2001 (Millions) (Millions)
EXHIBIT 18
NET LEGAL EXPENSES
FY01 Net Legal Expenses = $12.3 Million
Although University licensing personnel continue to be successful in negotiating reimbursement of a substantial amount of patent costs, it is expected that there will continue to be significant legal expenses associated with patenting and litigation as the technology transfer program matures, patent activities continue to accelerate, and relationships with inventors, sponsors and licensees become increasingly complex. 
OPERATING EXPENSES (Millions)
EXHIBIT 20
OPERATING EXPENSES AS A PERCENT OF TOTAL LICENSING REVENUES OPERATING EXPENSES
Operating expenses include funds spent for the administration of the technology transfer program at OTT and the six campus-based licensing offices. The scope of responsibilities and operations of these offices vary substantially and what is included as technology transfer operating expenses from location to location overlaps, but is not completely comparable. In general, operating expenses consist primarily of employee salaries, benefits, and expenses for equipment and supplies. In some instances, rent is included as well. Operating expenses rose 12% to $10.8 million in FY01 (Exhibit 19). This increase is due to expenses associated with the expansion of campus-based technology transfer activities and the support of a more broadly distributed approach to technology transfer administration. As indicated in Exhibit 20, operating expenses as a percentage of total licensing revenue was 12%, consistent with the level of the previous fiscal year.
INVENTOR SHARES
The University Patent Policy grants inventors the right to receive a portion of net income accruing to individual inventions. Under current policy, inventors receive 35% of net invention income. The calculation of inventor shares in any given fiscal year is based on invention income and expense activity through the close of the prior fiscal year. In FY01, 932 inventors received a total of $33.1 million in inventor share distributions based on invention financial activity through June 2000. Trends related to the number of inventors paid shares and the amount of inventor share payments are reflected in Exhibits 22 and 23. 
Income Distributions PAYMENTS TO JOINT HOLDERS
When an invention results from a collaboration between UC and non-UC researchers, multiple entities may become joint holders of the invention-related patents. In these instances, interinstitutional agreements are negotiated to establish which entity will be responsible for the management of patent prosecution and licensing of the invention, including the collection and distribution of invention income; such collaborations are relatively common. In FY01, 201 of 957 new disclosures (21%) included non-UC inventors and 48 new interinstitutional agreements were signed.
In FY01, $6.2 million in income was redistributed to other entities for more than 90 inventions covered by interinstitutional agreements. These payments are deducted from royalties and fees to arrive at adjusted gross income. The largest payment to a joint holder was $5.4 million to the University of Washington for the Hepatitis-B Vaccine. Over the past five years this invention has accounted for most of the UC payments to joint holders reflected in Exhibit 21. 
NET INCOME
The portion of technology transfer program income that is available to be redistributed to campuses to support ongoing research and education programs is net income. It is computed as income from royalty and fees less the sum of payments to joint holders, net legal and direct expenses, income distributions, and program operating expenses. Net income totaled $5.2 million in FY01. Increases in net legal and direct expenses, and inventor share payments contributed to an overall decline in net income as compared with FY00 (Exhibit 25).
EXHIBIT 25
NET INCOME* (Millions) * In order to facilitate trend analysis, this exhibit does not reflect royalties and inventor share payments related to an extraordinary $200 million legal settlement for Human Growth Hormone. If included, FY00 net income was $135.1 million.
In addition to these monies, starting in FY97, a portion of Short-Term Investment Pool (STIP) interest earnings on patent income has been distributed to the campuses and DOE Laboratories whose portfolios of OTT-managed cases yield a net income for the fiscal year. In FY01, STIP interest distributions totaled $256,486. 
RESEARCH ALLOCATION
The current Patent Policy requires that 15% of net royalty and fee income from each invention be designated for research-related purposes on the inventor' s campus or Laboratory. These monies are used in accordance with plans developed at each campus and Laboratory. The allocation, which applies to inventions disclosed on or after October 1, 1997, totaled $237,533 in FY01.
GENERAL FUND SHARE
The portion of University technology transfer income allocated to the UC General Fund as part of the State-approved budget totaled $5.1 million in FY01 (Exhibit 24). The General Fund share (previously called the "State share") is equal to 25% of the amount remaining after deducting direct expenses, inventor share payments, and payments to joint holders from total licensing revenue. Even though revenues increased, the General Fund share decreased in FY01 due largely to the FY01 increase in direct expenses and inventor shares.
EXHIBIT 24
GENERAL FUND SHARE (Millions)
Since 1988, technology transfer for the DOE Laboratories has been under the purview of Laboratory-based offices at Los Alamos National Laboratory (LANL), Lawrence Berkeley National Laboratory (LBNL), and Lawrence Livermore National Laboratory (LLNL Certain aspects of technology transfer processes differ at the DOE offices as compared with OTT and the campuses. For example, after an invention is disclosed and a determination is made to pursue licensing, there are some cases where the laboratory may be able to elect title to an invention on behalf of the University under the federal Bayh-Dole legislation, just as a campus does. In other cases, however, there must be a special request to DOE to enable The Regents to retain or be assigned title to the invention. Requests to assert copyright in software also must be made to DOE. In addition, whereas OTT and campus offices contract with attorneys at outside law firms for all of their patent prosecution activity, the Laboratories manage most U.S. patent filings internally through their own legal departments and contract out only for selected matters, particularly foreign prosecution. In addition, the fiscal year at the Laboratory offices ends September 30 in contrast to the June 30 end date for the fiscal year at OTT and the campus offices.
Information in this section pertains to the activities of the technology transfer offices of the Laboratories unless noted otherwise.
Technology Transfer Activity
In FY01, DOE Laboratory researchers disclosed 359 inventions and filed a total of 339 patent applications. One hundred fifty-eight (158) U.S. patents issued on DOE inventions.
The Laboratories completed 35 new options and licenses for patentable inventions and tangible research products (TRPs) in FY01, bringing the total number of active license and option agreements to 218 at the close of the fiscal year (Exhibit 30). Licensing of other types of intellectual property (e.g., copyrighted software) represent a significant additional element of current licensing activity. 
Financial Results
The DOE Laboratory-managed portfolios generated a total of $5.5 million in income during FY01, an increase of 25% over the prior year. Patent income for the Labs increased 33% as compared with FY00, while copyright income decreased 21% (Exhibit 31).
Information on DOE Laboratory patenting and licensing expenses is not provided in this report. Patent expenses are allowable costs under the University' s current contract with DOE and are not readily separable from other expenses of the legal departments. Similarly, operating expenses of the licensing function are not readily separable from other expenses of the technology transfer departments. Finally, income generated by the DOE Laboratories is not subject to the General Fund share assessment.
Inventor share payments of $1.9 million included $170,862 paid to authors of software. These payments were based on financial activity through 
